Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZN AstraZeneca	$72.44 +2.7%	$72.00	$61.24 ▼ $87.68	$224.65B	0.49	5.16 million shs	5.37 million shs
BNTX BioNTech	$104.94 +2.5%	$100.41	$76.53 ▼ $131.49	$25.18B	1.07	912,863 shs	729,399 shs
MRNA Moderna	$27.61 +2.1%	$29.52	$23.15 ▼ $170.47	$10.67B	2.23	7.41 million shs	7.54 million shs
PFE Pfizer	$24.19 +1.1%	$24.34	$20.92 ▼ $31.54	$137.19B	0.67	40.57 million shs	41.67 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZN AstraZeneca	+2.74%	+4.13%	+0.30%	+2.37%	-5.20%
BNTX BioNTech	+2.45%	+2.86%	+12.45%	-15.21%	+16.66%
MRNA Moderna	+2.15%	+1.43%	-0.40%	-29.96%	-75.23%
PFE Pfizer	+1.18%	+5.40%	-2.18%	-8.73%	-10.97%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AZN AstraZeneca	2.9283 of 5 stars	2.6	5.0	1.7	0.0	3.3	0.0	1.3
BNTX BioNTech	2.6238 of 5 stars	4.4	2.0	0.0	0.0	2.8	0.8	0.0
MRNA Moderna	4.3397 of 5 stars	4.0	1.0	0.0	4.6	1.9	2.5	1.3
PFE Pfizer	4.9849 of 5 stars	3.3	3.0	4.2	4.3	3.7	3.3	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AZN AstraZeneca	3.10	Buy	$88.00	21.48% Upside
BNTX BioNTech	2.89	Moderate Buy	$143.44	36.69% Upside
MRNA Moderna	2.04	Hold	$53.95	95.39% Upside
PFE Pfizer	2.53	Moderate Buy	$29.17	20.57% Upside

Current Analyst Ratings Breakdown

Latest AZN, PFE, BNTX, and MRNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/2/2025	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$78.00 ➝ $70.00
5/2/2025	MRNA Moderna	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$45.00 ➝ $40.00
5/2/2025	MRNA Moderna	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$32.00 ➝ $28.00
5/2/2025	MRNA Moderna	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	In-Line ➝ In-Line	$50.00 ➝ $32.00
4/30/2025	PFE Pfizer	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$24.00 ➝ $25.00
4/22/2025	PFE Pfizer	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Neutral	$24.00
4/17/2025	MRNA Moderna	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
4/15/2025	AZN AstraZeneca	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$75.00
4/9/2025	MRNA Moderna	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$39.00 ➝ $32.00
4/8/2025	PFE Pfizer	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$28.00 ➝ $24.00
4/8/2025	PFE Pfizer	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$32.00 ➝ $25.00

(Data available from 5/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AZN AstraZeneca	$54.07B	4.15	$6.14 per share	11.79	$13.18 per share	5.50
BNTX BioNTech	$2.75B	9.15	$4.51 per share	23.25	$92.17 per share	1.14
MRNA Moderna	$3.20B	3.34	N/A	N/A	$28.33 per share	0.97
PFE Pfizer	$62.46B	2.20	$3.79 per share	6.38	$15.81 per share	1.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AZN AstraZeneca	$7.04B	$2.26	32.05	14.49	1.42	13.01%	32.23%	12.31%	N/A
BNTX BioNTech	$1.01B	-$3.00	N/A	N/A	N/A	-15.16%	-2.35%	-2.05%	5/5/2025 (Estimated)
MRNA Moderna	-$3.56B	-$9.28	N/A	N/A	N/A	-110.04%	-28.74%	-21.83%	N/A
PFE Pfizer	$8.03B	$1.38	17.16	7.98	0.64	12.62%	19.47%	8.09%	N/A

Latest AZN, PFE, BNTX, and MRNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/5/2025	Q1 2025	BNTX BioNTech	-$2.68	N/A	N/A	N/A	$175.90 million	N/A
5/1/2025	Q1 2025	MRNA Moderna	-$2.92	-$2.52	+$0.40	-$2.52	$130.35 million	$108.00 million
4/29/2025	Q1 2025	AZN AstraZeneca	$1.10	$1.24	+$0.14	$0.93	$13.71 billion	$13.59 billion
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion
3/10/2025	Q4 2024	BNTX BioNTech	$0.38	$1.08	+$0.70	$1.15	$1.24 billion	$1.19 billion
2/6/2025	Q4 2024	AZN AstraZeneca	$1.10	$1.05	-$0.05	$0.48	$14.19 billion	N/A
2/4/2025	Q4 2024	PFE Pfizer	$0.48	$0.63	+$0.15	$0.07	$17.26 billion	$17.76 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AZN AstraZeneca	$2.06	2.84%	+1.98%	91.15%	N/A
BNTX BioNTech	$1.53	1.46%	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	7.11%	+2.50%	124.64%	16 Years

Latest AZN, PFE, BNTX, and MRNA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025
2/6/2025	AZN AstraZeneca	semi-annual	$1.03	2%	2/21/2025	2/21/2025	3/24/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AZN AstraZeneca	0.65	0.93	0.74
BNTX BioNTech	0.01	7.33	7.21
MRNA Moderna	N/A	3.67	3.62
PFE Pfizer	0.63	1.00	0.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AZN AstraZeneca	20.35%
BNTX BioNTech	15.52%
MRNA Moderna	75.33%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
AZN AstraZeneca	N/A
BNTX BioNTech	19.20%
MRNA Moderna	11.00%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AZN AstraZeneca	83,500	3.10 billion	N/A	Optionable
BNTX BioNTech	3,080	239.97 million	193.71 million	Optionable
MRNA Moderna	3,900	386.62 million	324.40 million	Optionable
PFE Pfizer	83,000	5.67 billion	5.66 billion	Optionable

AZN, PFE, BNTX, and MRNA Headlines

Recent News About These Companies

Leerink Partnrs Has Positive View of Pfizer FY2026 Earnings

May 3 at 8:47 AM | marketbeat.com

Alden Global Capital LLC Invests $6.22 Million in Pfizer Inc. (NYSE:PFE)

May 3 at 7:54 AM | marketbeat.com

Gallagher Fiduciary Advisors LLC Boosts Stake in Pfizer Inc. (NYSE:PFE)

May 3 at 6:45 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Sold by Mercer Global Advisors Inc. ADV

May 3 at 5:56 AM | marketbeat.com

Caisse DE Depot ET Placement DU Quebec Sells 6,485,010 Shares of Pfizer Inc. (NYSE:PFE)

May 3 at 5:37 AM | marketbeat.com

Pfizer (NYSE:PFE) Stock Price Up 0.4% - Here's What Happened

May 3 at 4:15 AM | marketbeat.com

FY2025 EPS Estimates for Pfizer Lifted by Cantor Fitzgerald

May 3 at 3:09 AM | americanbankingnews.com

Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (May 2025)

May 2 at 12:39 PM | 247wallst.com

Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (May 2025)

May 2 at 12:11 PM | 247wallst.com

South Plains Financial Inc. Buys New Shares in Pfizer Inc. (NYSE:PFE)

May 2 at 8:32 AM | marketbeat.com

FY2025 EPS Estimates for Pfizer Raised by Cantor Fitzgerald

May 2 at 8:11 AM | marketbeat.com

Itau Unibanco Holding S.A. Takes $13.30 Million Position in Pfizer Inc. (NYSE:PFE)

May 2 at 7:44 AM | marketbeat.com

Sulzberger Capital Advisors Inc. Takes $312,000 Position in Pfizer Inc. (NYSE:PFE)

May 2 at 7:10 AM | marketbeat.com

Voleon Capital Management LP Makes New $2.12 Million Investment in Pfizer Inc. (NYSE:PFE)

May 2 at 6:01 AM | marketbeat.com

3 No-Brainer Ultra-High-Yield Dividend Stocks That Are Begging to Be Bought in May

May 2 at 4:03 AM | fool.com

Arvinas (ARVN) Halts Development of Cancer Drug with Pfizer | ARVN Stock News

May 1 at 3:07 PM | gurufocus.com

Pfizer (NYSE:PFE) Stock Price Up 2% After Better-Than-Expected Earnings

May 1 at 11:17 AM | marketbeat.com

Do Wall Street Analysts Like Pfizer Stock?

May 1 at 10:19 AM | msn.com

UBS Group Boosts Pfizer (NYSE:PFE) Price Target to $25.00

May 1 at 10:14 AM | marketbeat.com

Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks

May 1 at 9:40 AM | zacks.com

Becker Capital Management Inc. Cuts Stake in Pfizer Inc. (NYSE:PFE)

May 1 at 7:35 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AZN, PFE, BNTX, and MRNA Company Descriptions

AstraZeneca NASDAQ:AZN

$72.44 +1.93 (+2.74%)

Closing price 05/2/2025 04:00 PM Eastern

Extended Trading

$72.50 +0.06 (+0.08%)

As of 05/2/2025 07:58 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

BioNTech NASDAQ:BNTX

$104.94 +2.51 (+2.45%)

Closing price 05/2/2025 04:00 PM Eastern

Extended Trading

$104.76 -0.19 (-0.18%)

As of 05/2/2025 07:45 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Moderna NASDAQ:MRNA

$27.61 +0.58 (+2.15%)

Closing price 05/2/2025 04:00 PM Eastern

Extended Trading

$27.48 -0.13 (-0.49%)

As of 05/2/2025 07:58 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Pfizer NYSE:PFE

$24.19 +0.26 (+1.09%)

Closing price 05/2/2025 03:59 PM Eastern

Extended Trading

$24.18 -0.01 (-0.02%)

As of 05/2/2025 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time